OMGA vs. KPTI, VXRT, DBVT, OTLK, CRDL, BCAB, MOLN, SGMO, LIFE, and SCLX
Should you be buying Omega Therapeutics stock or one of its competitors? The main competitors of Omega Therapeutics include Karyopharm Therapeutics (KPTI), Vaxart (VXRT), DBV Technologies (DBVT), Outlook Therapeutics (OTLK), Cardiol Therapeutics (CRDL), BioAtla (BCAB), Molecular Partners (MOLN), Sangamo Therapeutics (SGMO), aTyr Pharma (LIFE), and Scilex (SCLX). These companies are all part of the "medical" sector.
Karyopharm Therapeutics (NASDAQ:KPTI) and Omega Therapeutics (NASDAQ:OMGA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, media sentiment, analyst recommendations, institutional ownership, risk, valuation, community ranking and dividends.
Karyopharm Therapeutics has a beta of 0.16, suggesting that its share price is 84% less volatile than the S&P 500. Comparatively, Omega Therapeutics has a beta of 1.99, suggesting that its share price is 99% more volatile than the S&P 500.
Karyopharm Therapeutics has a net margin of -97.99% compared to Karyopharm Therapeutics' net margin of -3,147.92%. Omega Therapeutics' return on equity of 0.00% beat Karyopharm Therapeutics' return on equity.
Karyopharm Therapeutics received 503 more outperform votes than Omega Therapeutics when rated by MarketBeat users. Likewise, 72.02% of users gave Karyopharm Therapeutics an outperform vote while only 70.97% of users gave Omega Therapeutics an outperform vote.
Karyopharm Therapeutics currently has a consensus price target of $4.80, suggesting a potential upside of 336.36%. Omega Therapeutics has a consensus price target of $10.00, suggesting a potential upside of 364.04%. Given Karyopharm Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Omega Therapeutics is more favorable than Karyopharm Therapeutics.
In the previous week, Omega Therapeutics had 13 more articles in the media than Karyopharm Therapeutics. MarketBeat recorded 17 mentions for Omega Therapeutics and 4 mentions for Karyopharm Therapeutics. Karyopharm Therapeutics' average media sentiment score of 0.40 beat Omega Therapeutics' score of 0.00 indicating that Omega Therapeutics is being referred to more favorably in the news media.
Omega Therapeutics has lower revenue, but higher earnings than Karyopharm Therapeutics. Omega Therapeutics is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.
66.4% of Karyopharm Therapeutics shares are held by institutional investors. Comparatively, 97.5% of Omega Therapeutics shares are held by institutional investors. 4.3% of Karyopharm Therapeutics shares are held by company insiders. Comparatively, 57.0% of Omega Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Summary
Omega Therapeutics beats Karyopharm Therapeutics on 11 of the 18 factors compared between the two stocks.
Get Omega Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for OMGA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OMGA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Omega Therapeutics Competitors List
Related Companies and Tools
